Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 330-341

  Kiser, Jennifer J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiretroviral; Drug interactions; Investigational; Pharmacokinetics

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; ELVITEGRAVIR PLUS RITONAVIR; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; NEVIRAPINE; OMEPRAZOLE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RAVIROC; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS FOSAMPRENAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; TIPRANAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ABDOMINAL PAIN; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY; VOMITING;

EID: 42149126691     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fbaa6b     Document Type: Review

References (104)

1. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
2. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-417.
3. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of aCCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591-595. This study identified tropism use for the patients who screened for a study of the CCR5 antagonist, vicriviroc and evaluated associations between viral tropism and virologic and immunologic status.
4. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24 week results [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 104aLB.
5. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results of a phase 2b/3 study in the US and Canada [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 104bLB.
6. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract WESS104.
7. Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the maraviroc clinical development programme [abstract]. In: 11th European AIDS Conference; 24-27 October 2007; Madrid. Paris: EACS; 2007. Abstract LBP7.9/1.
8. Pfizer. Selzentry (maraviroc) product information; 8/2007 December 5, 2007. New York: Pfizer; 2007.
9. Scholler-Gyure M, Kakuda TN, de Smedt G, et al. Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1 negative volunteers [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract A-1427.
10. Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir+ritonavir on pharmacokinetics of MK-0518 [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A-0374.
11. Mathias A, Shen G, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007. Sydney. Geneva: IAS; 2007. Abstract TuPdB03.
12. Boehringer-Ingelheim. Aptivus (tipranavir) prescribing information; 10/2007 December 5, 2007. Ingelheim: Boehringer-Ingelheim; 2007.
13. Carter NJ, Keating GM. Maraviroc. Drugs 2007; 67:2277-2288.
14. Abel S, Ridgway C, Hamlin J, Davis J. An open, parallel group study to compare the pharmacokinetics, safety, and toleration of a single oral dose of maraviroc in subjects with mild and moderate hepatic impairment with subjects with normal renal function [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 8.
15. Rosario MC, Poland B, Sullivan J, et al. A pharmacokinetic- pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 2006; 42:183-191.
16. Abel S, Russell D, Ridgway C, et al. Effect of UK-427,857, on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women [abstract] In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 14-17 September 2003; Chicago. Washington, DC: American Society of Microbiology; 2003. Abstract A-1619.
17. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [abstract]. In: Fifth International Workshop on Clinical Pharmacology of HIV Therapy; 1-3 April 2004. Rome. Utrecht: Virology Education; 2004. Abstract 5.4.
18. Muirhead G, Russell D, Abel S, et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract]. In: Seventh International Congress on Drug Therapy in HIV Infection; Glasgow; 14-17 November 2004. Macclesfield: Thomson Gardiner-Caldwell Group Limited; 2004. Abstract P282.
19. Abel S, Taylor-Worth R, Ridgway C, et al. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK-427,857) in healthy volunteers [abstract]. In: 10th European AIDS Conference; 17-20 November 2005; Dublin. Paris: EACS; 2005. Abstract LBPE4.3/15.
20. Abel S, Ridgway C, Hamlin J, et al. An open, randomised, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. [abstract 55].
21. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312. Greater viral load declines were observed in treatment-experienced patients receiving vicriviroc versus placebo plus optimized background therapy. Six patients receiving vicriviroc versus two receiving placebo developed malignancies during the study period.
22. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologic breakthrough in treatment naive patients on a regimen of Combivir plus vicriviroc [abstract]. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Alexandria: CROI; 2006.
23. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299. This study demonstrated vicriviroc efficacy in 48 treatment-experienced patients after just 14 days of vicriviroc monotherapy.
24. Sansone-Parsons A, Saltzman M, Rosenberg M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers [abstract]. In: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City. Utrecht: Virology Education; 2005. Abstract 79.
25. Ghosal A, Ramanathan R, Yuan Y, et al. Identification of Human Liver Cytochrome P450 Enzymes Involved in Biotransformation of Vicriviroc, a CCR5 Receptor Antagonist. Drug Metab Dispos 2007; 35:2186-2195.
26. Sansone-Parsons A, Keung A, Caceres M, et al. The addition of tiprananvir has no impact on the pharmacokinetics of vicriviroc when co-administered with a potent CYP3A4 inhibitor such as ritonavir [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 57.
27. Flexner C, Keung A, Li C, et al. Pharmacokinetic/ pharmacodynamicmodeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment experienced HIV-infected patients (ACTG 5211) [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; Budapest, Hungary; April 16-18, 2007. Utrecht: Virology Education; 2007. Abstract 15.
28. Sansone-Parsons A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with difference protease inhibitors boosted by ritonavir [abstract]. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Alexandria: CROI; 2006. Abstract 582.
29. Sansone-Parsons A, Guillaume M, Kraan M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir [abstract]. In: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City. Utrecht: Virology Education; 2005. Abstract 85.
30. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-838.
31. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
32. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. This study demonstrated the efficacy of etravirine in patients on failing antiretroviral therapy with evidence of resistance to currently available NNRTI and at least three primary protease inhibitor mutations.
33. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. This study demonstrated the efficacy of etravirine in patients on failing antiretroviral therapy with evidence of resistance to currently available NNRTI and at least three primary protease inhibitor mutations.
34. Scholler-Gyure M, Kakuda TN, de Smedt G, et al. Pharmacokinetics of TMC125 in HIV-negative volunteers with mild or moderate hepatic impairment [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract A-1428.
35. Scholler-Gyure M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006. San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A0370.
36. Baede P, Piscitelli S, Graham N, Van't Klooster G. Drug interactions with TMC125, a potent next generation NNRTI [abstract]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2002; San Diego. Washington, DC: American Society of Microbiology; Abstract A1827.
37. Piscitelli S, Baede P, Van't Klooster G, Graham N. TMC125 does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers [abstract]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2002; San Diego. Washington, DC: American Society of Microbiology; Abstract A1824.
38. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects [abstract]. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Alexandria: CROI; 2006. Abstract 583.
39. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12:789-796.
40. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449-1455. This small study was the first to evaluate the efficacy and pharmacokinetics of the combination of etravirine and darunavir/ritonavir in treatment-experienced patients.
41. Anderson MS, Kakuda TN, Miller JL, et al. Pharmacokinetic evaluation of nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract TuPdB02.
42. Scholler-Gyure M, Debroye C, Vyncke V, et al. Effect of TMC125 on sildenafil pharmacokinetics [abstract]. In: Seventh International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon. Utrecht: Virology Education; 2006. Abstract 45.
43. Scholler-Gyure M, de Smedt G, Vanaken H, et al. TMC125 bioavailability is not affected by ranitidine and omeprazole [abstract]. In: XVI International AIDS Conference; 13-18 August 2006; Toronto. Geneva: IAS; 2006. Abstract TuPe0082.
44. Guillemont J, Pasquier E, Palandjian P, et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005; 48:2072-2079.
45. Pozniak A, Morales-Ramirez J, Mohapi L, et al. 48-Week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 144LB.
46. de Bethune MP, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile [abstract]. In: 12th Conference on Retroviruses and Opportunistic Infections; Boston. Alexandria: CROI; 2005; 22-25 February 2005. Abstract 556.
47. Hoetelmans R, Kerstens D, Marien K, et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation [abstract]. In: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City. Utrecht: Virology Education; 2005. Abstract 6.9
48. van Heeswijk R, Hoetelmans R, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation nonnucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract TuPdB01.
49. van Heeswijk R, Hoetelmans R, Kestens D, et al. The pharmacokinetic interaction between TMC278, a next generation nonnucleoside reverse transcriptase inhibitor, and once daily darunavir/ritonavir in HIV-negative volunteers [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract H-1042.
50. Hoetelmans R, van Heeswijk R, Kestens D, et al. Pharmacokinetic interaction between TMC278, an investigational nonnucleoside reverse transcriptase inhibitor, and lopinavir/ritonavir in healthy volunteers [abstract]. In: 10th European AIDS Conference; 17-20 November 2005; Dublin. Paris: EACS; 2005. Abstract 4.3/1.
51. van Heeswijk R, Hoetelmans R, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational nonnucleoside reverse transcriptase inhibitor (NNRTI) [abstract]. In: Seventh International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon. Utrecht: Virology Education; 2006. Abstract 74.
52. Hoetelmans R, Kestens D, Stevens M, et al. Pharmacokinetic interaction between the novel nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers [abstract]. In: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City. Utrecht: Virology Education; 2005. Abstract 18.
53. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant HIV [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 105bLB.
54. Cooper D, Gatell JM, Rockstroh J, et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract105aLB.
55. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133. This study demonstrated the efficacy of raltegravir in treatment-naïve patients.
56. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663.
57. Merck & Co Inc. Isentress (raltegravir) product information; 10/2007 December 5, 2007. Whitehouse Station: Merck & Co; 2007.
58. Anderson MS, Wenning LA, Moreau J, et al. Effect of raltegravir on the pharmacokinetics of oral contraceptives [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract A-1425.
59. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269. In this large phase II study, raltegravir showed better viral suppression at week 24 versus placebo when added to an optimized background regimen.
60. Mistry GC, Wenning LA, Merschman S, et al. Atazanavir and ritonavir increase plasma levels of MK-0518 [abstract]. In: Eighth International Congress on Drug Therapy In HIV Infection; 12-16 November 2006; Glasgow. Macclesfield: Thomson Gardiner-Caldwell Group Limited; 2006. Abstract P291.
61. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effect of ritonavir and efavirenz on the pharmacokinetics of MK-0518 [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006. San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A-0373.
62. Wenning LA, Friedman E, Kost JT, et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006. San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A-0375.
63. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007.
64. Mathias A, Jain A, Hui J, et al. Pharmacokinetic characterization of GS-9137 an HIV integrase inhibitor dosed with ritonavir [abstract]. In: Seventh International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon. Utrecht: Virology Education; 2006. Abstract 75.
65. Mathias A, West S, Enejosa J, Kearney BP. A pharmacokinetic interaction between lopinavir/ritonavir and elvitegravir [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract A-1418.
66. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45:274-279.
67. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007; 46:160-166.
68. Mathias A, Ramanathan S, Hinkle J, et al. Effect of atazanavir/r on the steadystate pharmacokinetics of elvitegravir. [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract A-1417.
69. Mathias A, Hinkle J, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and tipranavir/ritonavir [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract TuPdB06.
70. Ramanathan S, Mathias AA, Shen G, et al. Lack of a clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007.
71. Ramanathan S, West S, Abel S, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir plus maraviroc [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract H-1050.
72. Ramanathan S, West S, Kakuda TN, et al. Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125 [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract H-1049.
73. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 69.
74. Surleraux DL, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005; 48:1813-1822.
75. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S91-S94.
76. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. This pooled analysis demonstrated the efficacy of darunavir/ritonavir relative to other protease inhibitors in treatment-experienced patients. At week 48, 61% on darunavir/ritonavir versus 15% on comparator protease inhibitors had HIV-1 RNA reductions of >1 log.
77. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402. In 318 treatment experienced patients, darunavir/ritonavir demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than the comparator protease inhibitor.
78. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18. In 278 patients with one or more primary protease inhibitor mutations and HIV-1 RNA >1000 copies/ml, darunavir/ritonavir treatment resulted in greater virological and immunological responses compared to patients on other protease inhibitors at week 24.
79. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced. HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58. This study demonstrated the efficacy of darunavir/ritonavir versus lopinavir/ritonavir in patients naïve to lopinavir/ritonavir. At week 48, darunavir/ritonavir was noninferior to lopinavir/ritonavir in terms of HIV-1 RNA <400 copies/ml.
80. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV-treatment naive HIV-1 infected patients at week 48: ARTEMIS (TMC114-C211) [abstract]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Washington, DC: American Society of Microbiology; 2007. Abstract H-718b.
81. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007; 8:213-220. Patients coinfected with viral hepatitis are often not adequately represented in clinical trials of antiretroviral agents. This important study showed the efficacy and tolerability of darunavir/ritonavir in this patient population.
82. Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with impaired hepatic function [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract TuPdB05.
83. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739-756.
84. Hoetelmans RM, Marien K, De Pauw M, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007; 64:655-661.
85. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007; 12:509-514.
86. Tibotec. Prezista (darunavir) product information; 10/2006. Mechelen: Tibotec; 2006.
87. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8:241-248.
88. Sekar V, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitor TMC114 and lopinavir/ritonavir [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006. San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A-0367.
89. Sekar VJ, Lefebvre E, Marien K, et al. Pharmacokinetic Interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007; 29:795-801.
90. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007; 51:958-961.
91. Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine, and sertraline. In: Eighth International Congress on Drug Therapy In HIV Infection; 12-16 November 2006; Glasgow. Macclesfield: Thomson Gardiner-Caldwell Group Limited; 2006.
92. Sekar V, Lefebvre E, Felicione E, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone, and TMC114, a new protease inhibitor [abstract]. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006. San Francisco. Washington, DC: American Society of Microbiology; 2006. Abstract A-0368.
93. Sekar V, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid lowering agent pravastatin [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 54.
94. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337-1346.
95. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347-1356.
96. Markowitz M, Slater LN, Schwartz R, et al. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defic Syndr 2007; 45:401-410. This study illustrated the safety and efficacy of tipranavir/ritonavir after 80 weeks of therapy in 41 treatment-experienced patients.
97. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665-682.
98. Chen L, Sabo JP, Philip E, et al. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob Agents Chemother 2007; 51:2436-2444.
99. Vourvahis M, Dumond J, Patterson K, et al. Effects of tiprananvir/ritonavir on the activity of hepatic and intestinal cytochrome P450 3A4/5 and p-glycoprotein: implications for drug interactions [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 563.
100. Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir on the activity of cytochrome p450 (CYP) enzymes 1A2, 2C9, and 2D6 in healthy volunteers [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 52.
101. Kakuda TN, Kiser JJ. 7th International Workshop on Clinical Pharmacology of HIV Therapy 20-22 April 2006, Lisbon, Portugal. Expert Opin Pharmacother 2006; 7:1519-1533.
102. Durant J, Dellamonica P, Garraffo R, et al. The effect of tipranavir/ritonavir (TPV/r) on the pharmacokinetics of tadalafil in healthy volunteers [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 61.
103. van Heeswijk R, Sabo JP, Cooper D, et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200 mg BID and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers [abstract]. In: Fifth International Workshop on Clinical Pharmacology of HIV Therapy; 1-3 April 2004; Rome. Utrecht: Virology Education; 2004. Abstract 5.2.
104. la Porte CJL, Cameron DW, Sabo JP, et al. The effect of omeprazole, food, and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir (TPV/r) [abstract]. In: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest. Utrecht: Virology Education; 2007. Abstract 59.